XNASPRME
Market cap413mUSD
Jan 08, Last price
2.90USD
1D
-3.96%
1Q
-12.01%
IPO
-80.01%
Name
Prime Medicine Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-198m
L+62.64%
CFO
-165m
L+25.48%
Dividend
Sep 10, 20190.8 USD/sh
Profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 334,544 | 116,544 | |||
Unusual Expense (Income) | |||||
NOPBT | (334,544) | (116,544) | |||
NOPBT Margin | |||||
Operating Taxes | (279) | (948) | |||
Tax Rate | |||||
NOPAT | (334,265) | (115,596) | |||
Net income | (198,133) 62.64% | (121,821) -26.33% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 655 | 185,317 | |||
BB yield | -0.08% | -10.26% | |||
| Debt | |||||
Debt current | 18,552 | 11,694 | |||
Long-term debt | 17,990 | 45,796 | |||
Deferred revenue | (279) | ||||
Other long-term liabilities | 279 | ||||
Net debt | (85,123) | (249,927) | |||
| Cash flow | |||||
Cash from operating activities | (165,412) | (131,827) | |||
CAPEX | (8,724) | (16,095) | |||
Cash from investing activities | 18,711 | (47,096) | |||
Cash from financing activities | 655 | 181,494 | |||
FCF | (322,311) | (148,472) | |||
| Balance | |||||
Cash | 121,665 | 293,921 | |||
Long term investments | 13,496 | ||||
Excess cash | 121,665 | 307,417 | |||
Stockholders' equity | (491,343) | 66,735 | |||
Invested Capital | 647,323 | 278,280 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 90,969 | 97,209 | |||
Price | 8.86 -52.31% | 18.58 | |||
Market cap | 805,988 -55.38% | 1,806,147 | |||
EV | 720,865 | 1,916,534 | |||
EBITDA | (329,891) | (114,320) | |||
EV/EBITDA | |||||
Interest | 12,129 | ||||
Interest/NOPBT | |||||